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Abstract
BACKGROUND/OBJECTIVES—Osteoporosis affects approximately 2 million men in the 
U.S., however, few osteoporosis clinical studies include men. The objective of this study was to 
evaluate the evidence for efficacy of treatment options to reduce osteoporotic fracture risk for men.
DESIGN—Systematic review and meta-analysis.
DATA SOURCES—PubMed, Embase, and Cochrane Library databases.
STUDY SELECTION—Randomized clinical trials that evaluated the efficacy of a treatment for 
osteoporosis or low bone mineral density for adult male participants and reported fracture 
outcomes.
DATA EXTRACTION—Information extracted included participant sociodemographic 
characteristics; number of male participants; treatment/intervention(s) and comparator evaluated; 
study duration; and fracture outcome(s). Risk of bias of individual studies was assessed using 
measures recommended by the Cochrane Collaboration.
RESULTS—Twenty-four articles reporting results for 22 different studies (including 4868 male 
participants) met strict inclusion criteria. Fixed-effects meta-analyses using the Mantel-Haenszel 
method demonstrated significantly reduced risk of vertebral fractures with alendronate (RR 0.328, 
95% CI 0.155–0.692) and risedronate (RR 0.428, 95% CI 0.245–0.746), but not with calcitonin 
(RR 0.272, 95% CI 0.046–1.608) or denosumab (RR 0.256, 95% CI 0.029–2.238). For 
bisphosphonates as a treatment category, meta-analyses demonstrated significantly reduced risk of 
vertebral fractures (RR 0.368, 95% CI 0.252–0.537) and nonvertebral fractures (RR 0.604, 95% CI 
0.404–0.904). The meta-analysis finding that bisphosphonates significantly reduce nonvertebral 
fracture risk was not robust to sensitivity analysis.
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CONCLUSION—Bisphosphonates reduce the risk of vertebral and possibly nonvertebral 
fractures for men with osteoporosis. Further studies are needed to evaluate the efficacy of 
bisphosphonates for reducing nonvertebral fracture risk and the efficacy of non-bisphosphonates 
for reducing vertebral and nonvertebral fracture risk for men with osteoporosis.
Keywords
osteoporosis; fractures; systematic review; meta-analysis
INTRODUCTION
Osteoporosis affects 2 million men in the United States,1 and approximately 1 in 5 white 
men will sustain an osteoporotic fracture in his lifetime.2 Men are estimated to incur 29% of 
all osteoporotic fractures and account for 25% of total osteoporosis-related costs.3 
Furthermore, men have higher mortality rates after hip fracture than women, with nearly 1 in 
3 men over the age of 65 years who incur a hip fracture dying within the following year.4 
The morbidity, mortality, and costs secondary to osteoporotic fractures in the U.S. are 
considerable and likely to increase in upcoming years with the aging of the population.2–9
Despite the prevalence of osteoporosis among older men and potential severity of its health 
consequences, osteoporosis in men is significantly understudied compared with women; 
most osteoporosis clinical studies to date have not included male participants.10 FDA-
approved osteoporosis treatment options for men include alendronate, risedronate, 
zoledronic acid, teriparatide, and denosumab, and osteoporosis treatment for men is 
recommended by several organizations.11,12 We performed a systematic review and meta-
analysis of the evidence for fracture risk reduction for different osteoporosis treatment 
options for men.
METHODS
Data sources and search strategies
We developed broad literature search strategies for PubMed, Embase, and Cochrane Library 
databases to locate randomized clinical trials reporting on the efficacy of osteoporosis 
treatment options. We performed initial literature searches on 8/15/14 for Embase; 8/28/14 
for PubMed; and 11/28/14 for the Cochrane Library. The PubMed search was updated on 
3/18/16. The database search strategies are available upon request. We identified additional 
studies by reviewing the reference lists of topical review papers and studies meeting our 
inclusion criteria as well as studies identified by experts.
Study selection
We applied inclusion and exclusion criteria to literature identified with the search strategies 
to select studies of interest. We included studies that evaluated the efficacy of a treatment for 
adults with osteoporosis or low bone mineral density (BMD); were randomized clinical 
trials; reported separate data for male participants or had male participants only; and 
reported fracture outcomes, with provision of either numbers or percentages of men in each 
study group who sustained incident fractures. We included studies published in any 
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language, and had no restrictions on study participant comorbidities. We excluded studies in 
which not all participants were identified as having osteoporosis or low BMD (T-score ≤–1). 
We evaluated studies for inclusion in two stages – we first reviewed titles and abstracts, 
followed by full-text review of studies that were identified as potentially relevant after title/
abstract review.
Data extraction
Information extracted from eligible studies included study participant sociodemographic 
characteristics; number of male participants; study location; treatment/intervention(s) 
evaluated; comparator for evaluated treatment/intervention; duration of study/follow-up 
period for fracture outcomes; fracture outcome(s) evaluated; and results reported for fracture 
outcomes in intervention and comparator groups. For fracture outcomes, we extracted data 
on numbers of participants in the intervention and comparator groups who sustained incident 
fractures.
Data analysis
We qualitatively described included study characteristics and study quality. For study quality 
assessment, we used measures recommended by the Cochrane Collaboration for assessing 
risk of bias for individual studies, including criteria to evaluate risk of selection bias, 
performance bias, detection bias, attrition bias, and reporting bias.13 We also performed 
fixed-effects meta-analyses using the Mantel-Haenszel method14 to calculate summary 
relative risk of fracture estimates for each individual treatment option for which there were 
at least two studies with similar comparators and fracture outcomes assessed; and for 
bisphosphonates when considered as a treatment category. Between-study heterogeneity in 
each performed meta-analysis was assessed with I2 values. For studies that reported fracture 
outcomes for multiple follow-up time periods, we used the fracture outcomes reported for 
the longest follow-up time period when performing meta-analyses. For meta-analyses that 
included 3 or more studies, we also performed influence (sensitivity) analysis in which we 
excluded individual studies one at a time to assess whether meta-analysis findings were 
robust to exclusion of individual studies. We used Stata version 11.0 (StataCorp, College 
Station, TX) to perform these analyses.
RESULTS
Literature search and study selection
The literature searches identified a total of 6475 records (citations) for review; 2673 of these 
records were excluded because they were duplicates (same citation found in different 
databases), leaving 3802 unique records for review. Twenty-four of these records reporting 
results for 22 different studies met inclusion criteria.15–38 Figure 1 shows a flow diagram of 
the literature search and study selection.
Study characteristics
Supplementary Table S1 shows included study characteristics. Included studies were 
published between 1998 and 2013, number of male study participants ranged from 23 to 
1199, and study duration ranged from 1 to 3 years. Approximately half of the included 
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studies evaluated the efficacy of bisphosphonate medications, with more studies assessing 
alendronate or zoledronic acid than other bisphosphonates. Most included studies compared 
a treatment option to placebo and/or calcium and vitamin D only; very few had active 
comparators. A majority of studies included only men with primary osteoporosis and/or 
hypogonadal osteoporosis, and did not include men with other causes of secondary 
osteoporosis. Many of the included studies had largely white study participant populations. 
Commonly assessed osteoporosis fracture outcomes included all vertebral fractures 
(morphometric – detected by x-rays, including asymptomatic as well as symptomatic 
vertebral fractures); clinical vertebral fractures (meaning symptomatic vertebral fractures 
only); nonvertebral fractures; and clinical fractures (clinically symptomatic fractures at any 
site). Vertebral fractures were the most commonly assessed fracture outcomes, followed by 
nonvertebral fractures and clinical fractures.
Only one included study, a study by Boonen et al. evaluating zoledronic acid therapy, 
reported having sufficient statistical power for fracture outcomes for men, for the outcome of 
morphometric vertebral fractures.36 Only 4 studies reported relative risk, odds ratio, or 
hazard ratio of fracture for men in the intervention groups compared to the comparator 
groups;17,18,29,30,35,36 of these, 3 studies evaluating alendronate, risedronate, and zoledronic 
acid reported a statistically significant reduction in risk of fracture for men receiving the 
evaluated intervention/treatment compared to the comparator; all for the outcome of 
vertebral fractures,18,29,30,36 and only one study evaluating risedronate for the outcome of 
nonvertebral fractures.30 Only two included studies performed head-to-head comparisons of 
drugs that are FDA-approved for men – one study that compared teriparatide to 
alendronate,33 and another study that compared zoledronic acid to alendronate;38 neither of 
these studies reported relative risk for fracture outcomes. A majority of studies reported 
pharmaceutical company funding.15,16,19,21–25,27,28,31,33–36,38
Study quality and potential sources of bias
Supplementary Table S2 shows findings of our assessment of included study quality using 
criteria recommended by the Cochrane Collaboration for assessing risk of bias for individual 
studies. In general, studies did not sufficiently describe their methods of random sequence 
generation, allocation concealment, and whether all pre-specified outcomes in the study 
protocol were reported on in the pre-specified way to permit judgment of “low risk” or “high 
risk” of bias for these domains. Thus, most studies were assessed as “unclear risk” of bias 
for the categories of selection bias and reporting bias. A majority of studies reported 
blinding of fracture outcome assessment, and thus were assessed as low risk for detection 
bias. Studies were mixed with respect to domains of reporting of blinding of participants and 
personnel, as well as incomplete outcome data, which fall within categories of performance 
bias and attrition bias, respectively. No included study was assessed as low risk of bias for 
all evaluated domains, and thus no study received a summary assessment of low risk of bias. 
A slight majority of studies received a summary assessment of high risk of bias (due to at 
least one bias domain being assessed as high risk of bias), with the remainder of the studies 
receiving a summary assessment of unclear risk of bias.
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Meta-analyses
Sufficiently similar studies were available for separate meta-analyses for the outcome of 
vertebral fractures for alendronate, calcitonin, denosumab, and risedronate; for the outcome 
of nonvertebral fractures for alendronate; and for the outcome of clinical fractures with 
zoledronic acid. When considering bisphosphonates as a treatment category, sufficiently 
similar studies were available for outcomes of vertebral fractures, clinical vertebral fractures, 
nonvertebral fractures, and clinical fractures. Meta-analysis results are shown in Table 1. 
Forest plots for the meta-analyses are shown in Supplementary Figures S1–S10.
For individual treatment options, the meta-analyses findings demonstrated significantly 
reduced risk of vertebral fractures with alendronate (RR 0.328, 95% CI 0.155–0.692) and 
risedronate (RR 0.428, 95% CI 0.245–0.746), but not with calcitonin (RR 0.272, 95% CI 
0.046–1.608) or denosumab (RR 0.256, 9 5% CI 0.029–2.238). The meta-analyses findings 
for individual treatment options did not demonstrate significantly reduced risk of 
nonvertebral fractures with alendronate (RR 0.751, 95% CI 0.352–1.602) or clinical 
fractures with zoledronic acid (RR 0.742, 95% CI 0.436–1.263). When considering 
bisphosphonates as a treatment category, meta-analyses findings demonstrated significantly 
reduced risk of vertebral fractures (RR 0.368, 95% CI 0.252–0.537) and nonvertebral 
fractures (RR 0.604, 95% CI 0.404–0.904), but not clinical vertebral fractures (RR 0.398, 
95% CI 0.105–1.506) or clinical fractures (RR 0.791, 95% CI 0.500–1.253). Between-study 
heterogeneity in each performed meta-analysis was low as demonstrated by low I2 values.
The meta-analysis finding that bisphosphonates significantly reduce risk of vertebral 
fractures was robust to influence analysis, with summary estimates of relative risk of 
vertebral fractures with bisphosphonate therapy ranging from 0.353–0.391 with removal of 
individual studies, and the lower limit of the 95% CI ranging from 0.215–0.265 and the 
upper limit of the 95% CI ranging from 0.518–0.594 with removal of individual studies. 
However, the finding that bisphosphonates significantly reduce risk of nonvertebral fractures 
was sensitive to removal of the study by Ringe et al. in 2009 that evaluated risedronate 
therapy for men30 – when this study was removed from the analysis, the summary estimate 
for relative risk of nonvertebral fractures with bisphosphonate therapy was 0.715, with a 
95% CI of 0.382–1.337. The meta-analysis findings of nonsignificant reduction in the 
relative risk of clinical vertebral fractures or clinical fractures with bisphosphonates were 
robust to influence analysis, with results remaining nonsignificant with removal of any 
individual study in either analysis.
DISCUSSION
Relatively few randomized clinical trials have been performed to date to assess efficacy of 
osteoporosis treatment options for reducing fracture risk for men. Our meta-analysis findings 
for individual treatment options demonstrated that alendronate and risedronate significantly 
reduce risk of vertebral fracture for men; however, our meta-analyses for individual 
treatment options did not demonstrate evidence of statistically significant reduction in 
vertebral fracture risk for men with calcitonin or denosumab, nonvertebral fracture risk for 
men with alendronate, or clinical fracture risk for men with zoledronic acid. Our meta-
analyses findings for bisphosphonates when considered as a treatment category 
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demonstrated significantly reduced risk of vertebral fractures and nonvertebral fractures, but 
not clinical vertebral fractures or clinical fractures. Our results for significant reduction in 
the relative risk of nonvertebral fractures with bisphosphonate therapy were sensitive to the 
removal of the study by Ringe et al. in 2009 that demonstrated significantly reduced risk of 
nonvertebral fracture for men with risedronate therapy.30 There were insufficient data to 
perform meta-analyses for the efficacy of calcitriol, monoflourophosphate, parathyroid 
hormone, strontium ranealate, or teriparatide for reducing fracture risk for men.
Our meta-analyses were limited by the number of similar studies assessing each medication, 
with only 2 studies included in each separate meta-analysis of individual medications that 
we performed, and 3–6 studies included in each separate meta-analysis we performed for 
different fracture outcomes when evaluating bisphosphonates as a treatment category. 
Additionally, many of the included studies in our meta-analyses had small sample sizes. 
Furthermore, although one included study demonstrated significant reduction in 
morphometric vertebral fracture risk with zoledronic acid treatment,36 there were not two 
studies similar enough to perform a meta-analysis for the efficacy of zoledronic acid 
treatment on fracture outcomes for men. Moreover, our systematic review and meta-analysis 
findings are limited by the caveat that all studies included in our systematic review and 
meta-analysis were assessed as having unclear or high risk of bias. However, despite these 
limitations our findings suggest that in the absence of additional evidence bisphosphonates 
should preferentially be used as first-line osteoporosis treatment for men given evidence for 
their efficacy in reducing vertebral fracture risk, and possibly nonvertebral fracture risk as 
well. Our findings for the evidence of bisphosphonate efficacy to reduce fracture risk for 
men apply to individuals who have osteoporosis or low BMD by DXA criteria, or who have 
had a prior osteoporotic fracture, as the studies included in this systematic review and meta-
analysis included participants who met these criteria. Further studies are needed to evaluate 
the efficacy of osteoporosis treatment for men with risk factors for fracture who are not 
known to have osteoporosis or low BMD by DXA criteria or prior osteoporotic fracture.
Our study highlights the need for additional high-quality, sufficiently powered for fracture 
outcomes randomized clinical studies of osteoporosis treatment efficacy for men, 
particularly for nonvertebral fracture outcomes, and for non-bisphosphonate treatment 
options such as denosumab or teriparatide. Our findings also highlight the lack of active 
comparator randomized clinical trials of osteoporosis treatment for men; additional studies 
of osteoporosis treatment for men with active comparators would help clarify the relative 
efficacy of different treatment options for reducing fracture risk. Additionally, our findings 
reveal the need for greater diversity of participants in clinical trials of osteoporosis treatment 
for men; most included studies in our systematic review had largely white study participant 
populations. Finally, no study included in our systematic review had a duration greater than 
3 years, and thus the efficacy of longer osteoporosis treatment durations to reduce fracture 
risk for men is unknown – additional studies with longer durations would be helpful to 
evaluate the impact of osteoporosis treatment for longer durations than 3 years on fracture 
risk for men, similar to longer duration osteoporosis treatment studies that have 
demonstrated fracture risk reduction benefit for women.39
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Our study has several notable strengths. Our study is the most comprehensive systematic 
review and meta-analysis of randomized clinical trials of osteoporosis treatment efficacy for 
reducing fracture risk for men to date. A prior systematic review and meta-analysis on the 
topic of osteoporosis treatment efficacy for men by Schwarz et al. published in 2011 
included only five studies that reported fracture outcomes, and concluded that the evidence 
for osteoporosis treatment for men to reduce fracture risk was inconclusive.40 Our 
systematic review and meta-analysis, which included 22 randomized clinical studies of 
osteoporosis treatment for men that reported fracture outcomes, finds evidence for the 
efficacy of bisphosphonate medications for reducing risk of vertebral fractures and possibly 
nonvertebral fractures for men. Another strength of our study was the assessment of risk of 
bias of individual randomized clinical trials included in our systematic review using criteria 
recommended by the Cochrane Collaboration.
In conclusion, our findings support the use of bisphosphonates to reduce vertebral and 
possibly nonvertebral fracture risk for men with osteoporosis. Further studies are needed to 
evaluate the efficacy of bisphosphonates for reducing nonvertebral fracture risk for men, and 
to evaluate the efficacy of non-bisphosphonate treatment options such as denosumab or 
teriparatide to reduce vertebral and nonvertebral fracture risk for men.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Flow diagram of literature search and study selection
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Table 1
Meta-Analysis Results
Treatment Included studies Summary estimates of fracture relative risk (RR)
from meta-analysisa (95%CI; I2 valueb)
Alendronate Orwoll 200016,c & Ringe 200418 Vertebral fractures: 0.328 (0.155–0.692; I2=29.4%);
Nonvertebral fractures: 0.751 (0.352–1.602); I2=0.0%)
Calcitonin Toth 200520 & Trovas 200221 Vertebral fractures: 0.272 (0.046–1.608; I2=0.0%)
Denosumab Nakamura 201323 & Orwoll 201224 Vertebral fractures: 0.256 (0.029–2.238; I2=0.0%)
Risedronate Boonen 200928 & Ringe 200930 Vertebral fractures: 0.428 (0.245–0.746; I2=27.4%)
Zoledronic acid Boonen 201135 & Boonen 201236 Clinical fractures: 0.742 (0.436–1.263; I2=0.0%)
Any bisphosphonate
(alendronate,
ibandronate,
risedronate, or
zoledronic acid)
Boonen 200928, Boonen 201236, Orwoll 200016,
Orwoll 201025, Ringe 200418, Ringe 200930
(vertebral fractures meta-analysis);
Boonen 201236, Orwoll 200016, Orwoll 201025
(clinical vertebral fractures meta-analysis)d;
Boonen 201236, Orwoll 200016, Ringe 200418, Ringe
200930 (nonvertebral fractures meta-analysis);
Boonen 200928, Boonen 201135, Boonen 201236,
Orwoll 201025 (clinical fractures meta-analysis)
Vertebral fractures: 0.368 (0.252–0.537; I2=0.0%);
Vertebral fractures (clinical only): 0.398 (0.105–1.506;
I2=0.0%);
Nonvertebral fractures: 0.604 (0.404–0.904; I2=0.0%);
Clinical fractures: 0.791 (0.500–1.253; I2=0.0%)
a
Fixed-effects meta-analysis using Mantel-Haenszel method
b
Percentage of variation across studies attributable to heterogeneity
c
For Orwoll 2000 study, vertebral fracture results reported when using quantitative assessment method were used for meta-analysis
dShimon 2005 study excluded from analysis due to no fracture events in intervention or comparator groups
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